The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
Abstract
PURPOSE: To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer. PATIENTS AND METHODS: We prospectively randomized 605 patients to treatment with oral capecitabine for 14 days every 3 weeks or 5-FU/LV by rapid IV injection daily for 5 days in 4-week cycles. RESULTS: The overall objective tumor response rate among all randomized patients was significantly higher in the capecitabine group (24.8%) than in the 5-FU/LV group (15.5%; P = .005). In the capecitabine and 5-FU/LV groups, median times to disease progression were 4.3 and 4.7 months (log-rank P = .72), median times to treatment failure were 4.1 and 3.1 months (P = .19), and median overall survival times were 12.5 and 13.3 months (P = .974), respectively. Capecitabine, compared with bolus 5-FU/LV treatment, produced a significantly lower incidence (P < .0002) of diarrhea, stomatitis, nausea, and alopecia. Patients treated with capecitabine also displayed lower incidences of grade 3/4 stomatitis and grade 3/4 neutropenia (P < .0001) leading to significantly less neutropenic fever/sepsis. Grade 3 hand-foot syndrome (P < .00001) and grade 3/4 hyperbilirubinemia were the only toxicities more frequently associated with capecitabine than with 5-FU/LV treatment. CONCLUSION: Oral capecitabine was more active than 5-FU/LV in the induction of objective tumor responses. Time to disease progression and survival were at least equivalent for capecitabine compared with the 5-FU/LV arm. Capecitabine also demonstrated clinically meaningful benefits over bolus 5-FU/LV in terms of tolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Parkin, D. M., Pisani, P., & Ferlay, J. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.33 · Cited by 3,376
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGiacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Cited by
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialCapecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Self-citationCassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 862
Self-citationWalko, C. M., & Lindley, C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.005 · Cited by 659
Koopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F. L., de Jong, R. S., Rodenburg, C. J., Vreugdenhil, G., Loosveld, O. J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61086-1 · Cited by 630
Watanabe, T., Itabashi, M., Shimada, Y., Tanaka, S., Ito, Y., Ajioka, Y., Hamaguchi, T., Hyodo, I., Igarashi, M., Ishida, H., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0801-z · Cited by 590
Metastatic Colorectal Cancer: Current State and Future Directions
Fakih, M. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7633 · Cited by 527
Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Systemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G.-J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30686-7 · Cited by 444
5-fluorouracil and cardiotoxicity: a review
Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., Herrmann, J., Lerman, A., & Grothey, A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918780140 · Cited by 433
Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf089 · Cited by 425
Self-citationCutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601676 · Cited by 401
Self-citationChemotherapy: a double-edged sword in cancer treatment
Behranvand, N., Nasri, F., Zolfaghari Emameh, R., Khani, P., Hosseini, A., Garssen, J., & Falak, R. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03013-3 · Cited by 397
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review
Malet-Martino, M., & Martino, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-4-288 · Cited by 382
Colorectal cancer: From prevention to personalized medicine
Binefa, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6786 · Cited by 382
Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., Largiadèr, C. R., Jennings, B. A., Marinaki, A. M., Sanderson, J. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00286-7 · Cited by 381
Cardiotoxicity of Cancer Therapy
Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., & Perry, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.789 · Cited by 372
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Deenen, M. J., Meulendijks, D., Cats, A., Sechterberger, M. K., Severens, J. L., Boot, H., Smits, P. H., Rosing, H., Mandigers, C. M. P. W., Soesan, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1325 · Cited by 360
Cost of Cancer Care: Issues and Implications
Meropol, N. J., & Schulman, K. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6081 · Cited by 351
Allegra, C. J., Yothers, G., O’Connell, M. J., Beart, R. W., Wozniak, T. F., Pitot, H. C., Shields, A. F., Landry, J. C., Ryan, D. P., Arora, A., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv248 · Cited by 326
Douillard, J.-Y., Hoff, P. M., Skillings, J. R., Eisenberg, P., Davidson, N., Harper, P., Vincent, M. D., Lembersky, B. C., Thompson, S., Maniero, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.123 · Cited by 323
Self-citationDamaraju, V. L., Damaraju, S., Young, J. D., Baldwin, S. A., Mackey, J., Sawyer, M. B., & Cass, C. E. (2003) · Oncogene · doi:10.1038/sj.onc.1206952 · Cited by 318
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
Kelly, H., & Goldberg, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.749 · Cited by 316
Adjuvant Treatment of Colorectal Cancer
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., & Mayer, R. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.3.168 · Cited by 306
Porschen, R., Arkenau, H.-T., Kubicka, S., Greil, R., Seufferlein, T., Freier, W., Kretzschmar, A., Graeven, U., Grothey, A., Hinke, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2684 · Cited by 280
Ruo, L., Gougoutas, C., Paty, P. B., Guillem, J. G., Cohen, A. M., & Wong, D. W. (2003) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(03)00136-4 · Cited by 277
S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008
Schmiegel, W., Reinacher-Schick, A., Arnold, D., Graeven, U., Heinemann, V, Porschen, R., Riemann, J., Rödel, C., Sauer, R., Wieser, M., et al. (2008) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027726 · Cited by 274
Claret, L., Girard, P., Hoff, P. M., Van Cutsem, E., Zuideveld, K. P., Jorga, K., Fagerberg, J., & Bruno, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0807 · Cited by 272
Self-citationCarmichael, J., Popiela, T., Radstone, D., Falk, S., Borner, M., Oza, A., Skovsgaard, T., Munier, S., & Martin, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.129 · Cited by 268
Díaz-Rubio, E., Tabernero, J., Gómez-España, A., Massutí, B., Sastre, J., Chaves, M., Abad, A., Carrato, A., Queralt, B., Reina, J. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.8467 · Cited by 268
Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
Haller, D. G., Cassidy, J., Clarke, S. J., Cunningham, D., Van Cutsem, E., Hoff, P. M., Rothenberg, M. L., Saltz, L. B., Schmoll, H.-J., Allegra, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2090 · Cited by 252
Self-citationCassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr031 · Cited by 90
Self-citationCunningham, D., Sirohi, B., Pluzanska, A., Utracka-Hutka, B., Zaluski, J., Glynne-Jones, R., Koralewski, P., Bridgewater, J., Mainwaring, P., Wasan, H., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn638 · Cited by 62
Are claims of equivalency in digestive diseases trials supported by the evidence?☆
Tinmouth, J. M., Steele, L. S., Tomlinson, G., & Glazier, R. H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.005 · Cited by 25
The Role of Intestinal Microbiota in Metastatic Colorectal Cancer Patients Treated With Capecitabine
Aarnoutse, R., Ziemons, J., de Vos-Geelen, J., Valkenburg-van Iersel, L., Wildeboer, A. C. L., Vievermans, A., Creemers, G.-J. M., Baars, A., Vestjens, H. J. H. M. J., Le, G. N., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.10.004 · Cited by 19
Metadata
- Authors
- Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., Burger, H. U., Osterwalder, B., Wong, A. O., & Wong, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-04-15
- Volume
- 19
- Issue
- 8
- Pages
- 2282-2292
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1910716144
- Cited by
- 1,130
- References
- 35
- FWCI
- 30.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.